Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 18;10(2):e034331.
doi: 10.1136/bmjopen-2019-034331.

Local and systemic morbidities of de novo metastatic prostate cancer in Singapore: insight from 685 consecutive patients from a large prospective Uro-oncology registry

Yu Guang Tan  1 , Leonard Pang  2 , Farhan Khalid  3 , Randy Poon  3 , Hong Hong Huang  1 , Kenneth Chen  1 , Kae Jack Tay  1 , Weber Lau  1 , Christopher Cheng  1 , Henry Ho  1 , John Yuen  1
Affiliations

Local and systemic morbidities of de novo metastatic prostate cancer in Singapore: insight from 685 consecutive patients from a large prospective Uro-oncology registry

Yu Guang Tan et al. BMJ Open. .

Abstract

Objective: To evaluate the incidence and management of local and systemic complications afflicting patients with de novo metastatic prostate cancer (mPCa) in Singapore.

Design: Retrospective analysis of a large prospective Uro-oncology registry of mPCa.

Setting: This study is carried out in a tertiary hospital in Singapore.

Participants: We reviewed our institution's prospectively maintained database of 685 patients with mPCa over a 20-year period (1995-2014). Patients with non-mPCa or those progressed to metastatic disease after previous curative local treatments were excluded.

Primary and secondary outcome measures: The primary outcome was to evaluate the systemic and local morbidity rates associated with mPCa. Local complication was defined as the need for palliative procedures to relieve urinary obstruction, worsening renal function or refractory haematuria, while systemic complication was related to radiographic evidence of skeletal-related pathological fractures. Secondary outcomes analysed were the management and overall survival patterns over 20 years.

Results: 237 (34.6%) patients required local palliative treatments. 88 (12.8%) patients presented with acute urinary retention, 23 patients (9.7%) required repetitive local palliative treatments. On multivariate analyses, prostate-specific antigen >100 (p=0.02) and prostate volume >50 g (p=0.03) were independent prognostic factors for significant obstruction requiring palliative procedures. 118 (17.2%) patients developed skeletal fractures, with poor Eastern Cooperative Oncology Group Performance (ECOG) status (p=0.01) and high volume bone metastasis (p<0.01) independently predictive of skeletal fractures. Altogether, 653 (95.3%) patients received androgen deprivation therapy (ADT), with the median time to castrate resistance of 21.4 months (IQR 7-27). The median overall survival was 45 months (IQR 20-63), with prostate cancer mortality of 81.4%. Improved overall survival was observed from 41.6 months (1995-1999) to 47.8 months (2010-2014) (p<0.01).

Conclusion: Morbidities and complications arising from mPCa are more common and debilitating than we thought, often requiring immediate palliative treatments, while many necessitate repeated interventions with progression.

Keywords: SRF; channel TURP; metastasis; morbidity; prostate disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Type of palliative treatments for urinary obstruction. TURP, transurethral resection of prostate; TURBNI, transurethral bladder neck incision; PCN, percutaneous nephrostomy.
Figure 2
Figure 2
Predictors of overall survival. (A) ECOG status; (B) Gleason score; (C) presence of visceral metastasis; (D) presence of high volume bone metastasis.
Figure 3
Figure 3
Overall survival across interim 5 yearly analyses.
See this image and copyright information in PMC

References

    1. National Registry of Diseases Office Singapore cancer registry annual Registry report 2015 – statistics, 2015. Available: https://www.nrdo.gov.sg/publications/cancer [Accessed 29 May 2019].
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30. 10.3322/caac.21387 - DOI - PubMed
    1. Chen R, Ren S, Yiu MK, et al. . Prostate cancer in Asia: a collaborative report. Asian J Urol 2014;1:15–29. 10.1016/j.ajur.2014.08.007 - DOI - PMC - PubMed
    1. Bill-Axelson A, Holmberg L, Ruutu M, et al. . Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708–17. 10.1056/NEJMoa1011967 - DOI - PubMed
    1. Zelefsky MJ, Reuter VE, Fuks Z, et al. . Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008;179:1368–73. 10.1016/j.juro.2007.11.063 - DOI - PMC - PubMed

Substances